icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
suNYgn8H86sMU5Gs
Listen
